A unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing

Background

Amikacin is widely used in paediatric patients, but developmental changes in drug disposition from birth through to adolescence make dose optimization challenging. Existing population pharmacokinetic (PopPK) models are typically developed for specific paediatric age groups, limiting their applicability across the full paediatric age range.